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Abstract 
Secreted proteins play essential roles in the process of tumorigenesis, and the analysis of 
tumor-secreted proteins has been suggested as a promising strategy for identifying 
cancer biomarkers.  In this study, we performed proteomic analysis to identify proteins 
secreted from bladder cancer cell lines that are recognized by autoantibodies in sera from 
patients with bladder cancer.  In addition, autoantibodies against the identified proteins 
were validated using a dot-blot array with sera from patients with bladder cancer and 
normal controls.  As the results, we detected twenty-five and thirty-two immunoreactive 
spots in sera from patients with high- and low-grade bladder cancer, respectively.   In 
addition, validation analysis revealed that serum IgG levels of anti-calreticulin and 
matrix metalloproteinase-2 (MMP2) autoantibodies were significantly higher in bladder 
cancer patients than in normal controls (both P < 0.05).  Furthermore, the serum IgG 
level of anti-MMP2 autoantibody was significantly higher in patients with high- 
compared to low-grade bladder cancer (P < 0.05).  On multivariate analysis, the serum 
IgG level of anti-MMP2 autoantibody was an independent predictor of cancer-specific 
survival (P < 0.05).  Based on these findings, serum IgG levels of anti-calreticulin and 
MMP2 autoantibodies may be novel biomarker candidates for bladder cancer and its 
clinical outcome. 
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1. Introduction 
Bladder cancer (BC) is the 7th most common cancer in men and the 17th most 
common in women in the world.  The incidence of BC have been increasing in 
Japan, and it was about 20 and 5 per 100,000 Japanese males and females in 2002 
(22).  Approximately 75–85% of BC are diagnosed as non–muscle-invasive 
bladder cancer (NMIBC) at the first diagnosis, and around 70% of cases present as 
pTa, 20% as pT1, and 10% as carcinoma in situ lesions (23).   NMIBC has a 
tendency to recur (50-70%) and may progress (10-20%) to a higher grade and/or 
muscle-invasive BC in time, which might lead to high cancer-specific mortality 
(46).  
The histological tumor grade is one of the clinical factors associated with 
outcomes of patients with NMIBC.  High-grade NMIBC generally shows a more 
aggressive behavior than the low-grade form, and increases the risk of a poorer 
prognosis (3, 32).  Due to the unfavorable prognosis associated with high-grade 
NMIBC, differential diagnosis between high- and low-grade NMIBC might be 
crucial for more appropriate follow-up and aggressive treatment.  Cystoscopy 
and urine cytology are commonly used techniques for the diagnosis and 
surveillance of BC.  Cystoscopy can identify most papillary and solid lesions, but 
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is markedly invasive to the patients, whereas urine cytology is limited by operator 
dependence and low sensitivity.  For these reasons, some tumor markers have 
been investigated (e.g. BTAstat, NMP22), but their sensitivity and specificity are 
limited.  Also, they are unable to predict the clinical outcome of BC patients (1, 
42, 44).  Therefore, one of the most important clinical challenges is the 
identification of novel biomarkers for aggressive NMIBC destined to recur and 
progress following initial treatment that can be used to predict the outcome of 
patients. 
Proteins secreted from tumor cells reflect the various states of the tumor in 
real time and under specific conditions, and their expression patterns are 
different from normal cell components.  Thus, proteins secreted into several body 
fluids, such as the serum, urine, cerebrospinal fluid, tears, and saliva from tumor 
cells and conditioned media of cultured tumor cells have been investigated.  
Approximately 20-25% of cellular proteins are secreted into extracellular spaces, 
and these proteins play important roles in differentiation, invasion, metastasis, 
angiogenesis, and the regulation of cell-to-cell and cell-to-extracellular matrix 
interactions (6, 40, 48).  It has been suggested that tumor-secreting proteins are 
a promising source of diagnostic biomarkers in tumors (33). 
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   Tumor-associated antigens released into the bloodstream could induce a 
humoral immune response and generate autoantibodies (AAbs) (11).  
Interestingly, the immune response to such antigens generates marked biological 
amplification even though tumor-associated antigens are undetectable in sera in 
the early stage of tumorigenesis (19).  Hundreds of tumor-associated antibodies 
have been identified, and the potential for using AAbs as a novel biomarker useful 
for cancer diagnosis has been discussed (17).  Furthermore, recent studies based 
on AAb profiling of cancer patients have suggested that AAbs may not be only 
diagnostic but also prognostic biomarkers (24).  
In this study, we performed two-dimensional gel electrophoresis (2-DE) 
combined with immunoblot analysis to identify tumor-associated secreted 
antigenic proteins that elicit a humoral response in sera from BC patients.  By 
comparing immunoreactive patterns in sera from high- and low-grade BC patients, 
novel tumor markers associated with the histological grade were obtained.  The 
identified proteins were further validated by dot-blot analysis with a large 
number of sera from patients with BC and normal controls.  Moreover, the 
relationships between serum IgG levels of AAbs and clinicopathological factors of 
BC patients were also evaluated. 
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2. Materials and Methods 
2-1. Serum samples 
Ninety-five serum samples from BC patients who had not received any therapy 
at Kitasato University Hospital were collected and stored at -80 °C until use.  
The 2002 TNM and WHO classifications were used for determination of the 
pathological stage and histological grade of the tumor.  Clinical characteristics of 
BC patients whose sera were collected are shown in Table 1.  Thirty-five serum 
samples from healthy donors were also collected and used as a control.  This 
study was approved by the Ethics Committee of Kitasato University School of 
Medicine.  All patients were informed of the aim of the study and gave consent 
for the use of their samples. 
 
2-2. Cell culture and sample preparation for proteomic analysis 
The human bladder cancer cell lines TCCSUP, T24, 5637, and RT4 were 
purchased from the American Type Culture Collection (Manassas, VA, USA).  
These cell lines were grown in RPMI-1640 (SIGMA Aldrich Corp., St. Louis, MO, 
USA) supplemented with 10% fetal bovine serum (Biowest, Nuaillè, France), 100 
units/mL of penicillin, and 100 μg/mL of streptomycin (Life Technologies Corp., 
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Carlsbad, CA, USA) at 37°C in 5% CO2 and 95% humidified air and harvested 
when they reached a confluency of 60-70%.  Then, cells were washed 3 times with 
phosphate-buffered saline without divalent ions (PBS(-)), and additionally 
incubated with serum-free medium (Hybridoma-SFM; Life Technologies Corp.) for 
48 h.  The collected culture supernatants were subjected to serial centrifugation 
to remove cells at 200×g for 20 min at room temperature (R/T) and cell debris at 
2,000×g for 30 min at 4 °C, respectively.  Forty milliliters of culture supernatants 
from each cell line was concentrated by ultrafiltration (Amicon Ultra-15 
centrifugal filter units with a 30-kDa molecular weight cutoff membrane; 
Millipore Corp., Billerica, MA, USA), according to the manufacturer’s instructions.  
The concentrated samples were precipitated and components interfering with 
2-DE were removed with a 2-D Clean-up Kit (GE Healthcare Bio-Sciences Corp., 
Piscataway, NJ, USA), according to the manufacturer’s instructions.  
Precipitated samples were solubilized in lysis buffer (7 M urea, 2 M thiourea, 2% 
3-[(3-cholamidopropyl) dimethylammonio] propanesulfonic acid, 10 mM 
tris(2-carboxyethyl)-phosphine hydrochloride (TCEP), 2.5% pH 3-10 pharmalyte 
(GE Healthcare Bio-Sciences Corp.), and one tablet of complete mini EDTA-free 
protease inhibitors (Roche Diagnostics, Mannheim, Germany) per 10 mL of 
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solution) using an ultrasonic homogenizer (VP-050; TAITEC Co., Ltd., Saitama, 
Japan), and centrifuged at 20,000×g for 30 min at 4°C.  Finally, the protein 
concentration was quantified using Protein Assay Reagent (Bio-Rad Laboratories, 
Hercules, CA, USA). 
 
2-3. Two-dimensional gel electrophoresis 
2-DE was performed according to our previous study (30).  The 
first-dimensional agarose isoelectric focusing gel (75 mm in length and 2.5 mm in 
inner diameter) was made with single pharmalyte pH 3-10 (GE Healthcare 
Bio-Sciences Corp.).   Thirty-five micrograms of each protein extracted from 
culture supernatants of four cell lines were equally mixed and applied to the 
cathodic end of the agarose isoelectric focusing gel, and loaded in stepwise 
voltages as follows: 100 V: 20 min, 300 V: 15 min, 500 V: 15 min, 700 V: 60 min, 
and 900 V: 150 min at 4°C.  After fixation in 10% trichloroacetic acid and 5% 
sulfosalicylic acid for 3 min at R/T with mild shaking, agarose gels were placed in 
distilled water and washed 3 times for 15 min each at R/T.  The agarose gel was 
equilibrated in equilibration buffer (0.06 M Tris-HCl (pH 6.8), 2% sodium dodecyl 
sulfate (SDS), 10% glycerol, 5% 2-mercaptoethanol, and 0.02% bromophenol blue 
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(BPB)).   Then, the agarose gel was placed on the top of the second-dimensional 
10% polyacrylamide gel, and loaded with a constant current at 20 mA/ gel.  
 
2-4. Immunoblotting 
The separated proteins on 2-DE gels were transferred to polyvinylidene 
difluoride (PVDF) membranes (Millipore Corp.) overnight at R/T with a constant 
voltage at 10 V. After blocking with 0.5% casein for 60 min, the membranes were 
reacted with 20-times-diluted mixed sera of four NMIBC patients each with high- 
or low-grade BCs with 0.05% casein/TBST for 15 h at 4°C.  The membranes were 
washed 3 times with Tris-buffered saline containing 0.1% tween20 (TBST) and 
reacted with 1,000-times-diluted horseradish peroxidase (HRP)-conjugated rabbit 
anti-human IgG antibody (DAKO, Glostrup, Denmark) with 0.05% casein/TBST 
for 30 min at R/T.  After washing another 3 times with TBST, immunoreactive 
spots on the membrane were visualized with stable DAB solution (Life 
Technologies Corp.) for 15 min at R/T.  The visualized images were digitized with 
a high-resolution scanner (GT-9800; Seiko Epson Corp., Tokyo, Japan).  
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2-5. Identification of proteins recognized by autoantibodies 
For the identification of proteins recognized by autoantibodies, the separated 
proteins on 2-DE gels were stained by coomassie brilliant blue (CBB) (PhastGel 
Blue R; GE Healthcare Bio-Sciences Corp.) solution, and staining images were 
digitized with a high-resolution scanner.  In order to match the immunoreactive 
spots on the membrane with protein spots on the gel, both digitized images were 
overlayed using Adobe photoshop software (version 7.0; Adobe Systems Inc., San 
Jose, CA, USA).  The protein spots matched with the immunoreactive spots were 
manually excised from the gel and destained with 50% acetonitrile/50 mM 
NH4HCO3 until they became colorless.  The pieces of gel were dehydrated with 
100% acetonitrile and dried under vacuum conditions.  They were then 
rehydrated in 10 μL of trypsin solution containing 10 ng/μL trypsin (Trypsin Gold, 
Mass Spectrometry Grade; Promega, Madison, WI, USA) for 45 min at 4°C and 
incubated for 24 h at 37°C with a minimum volume of trypsin solution and 7 μL of 
25 mM NH4HCO3.  After incubation, the digested tryptic peptide solutions were 
collected, and the gel was washed once with 7 μL of 5% trifluoroacetic acid/50% 
acetonitrile and washed solutions were collected in the same tube.  They were 
then subjected to peptide mass fingerprint (PMF) and MS/MS analyses for protein 
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identification.  Finally, they were spotted on a Prespotted AnchorChip 96 Set for 
Proteomics (Bruker Daltonics, Bremen, Germany) and analyzed with 
MALDI-TOF/TOF-MS using Autoflex Ⅲ (Bruker Daltonics) and FlexAnalysis 
software (version 3.0.96; Bruker Daltonics) according to the manufacturer’s 
instructions.  PMF spectra were acquired in the positive reflector mode in a mass 
range from 320 to 4,000 Da using the default parameters with the main 
parameters.  The calibration of PMF spectra was carried out using the calibrant 
spots equipped with AnchorChip according to the manufacturer’s 
recommendations.  Irrelevant masses including matrix (855.09, 861.10, 877.10) 
and autodigested tryptic masses (842.51, 1,045.56, 2,211.05, 2,225.14, 2,283.20, 
2,807.20) were automatically and manually excluded from the analysis.  MS 
spectra derived from PMF analysis was further validated by MS/MS analysis.  
Some of the strongest peaks in each MS spectrum were selected as precursor ions, 
and MS/MS spectra were acquired in the positive LIFT mode using the default 
parameters with the main parameters.  The PMF and MS/MS spectra were 
processed with FlexAnalysis and BioTools software (version 3.0.183; Bruker 
Daltonics).  Furthermore, the combined spectrum data were connected with the 
MASCOT Server (version 2.3; Matrix Science, London, UK, 
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www.matrixsciences.com) and database searches were run using the IPI human 
database (version 3.82; 92,104 sequencies; 36,547,220 residues, 
http://www.ebi.ac.uk/IPI/Databases.html) with the following parameters: enzyme 
specificity, trypsin; variable modification, oxidation with methionine, 
propionamide, and pyridylethyl with cysteine; maximum of one missed cleavage 
site; peptide mass tolerance of 100 ppm ; MS/MS (fragment ion) tolerance of 0.8 
Da.  The Mascot score of a hit above 62 and p < 0.05 was set as the threshold for 
protein identification. 
 
2-6. Dot-blot analysis 
Based on the results of both the above proteomic approaches and database 
information from Uniprot (http://www.uniprot.org/), secreted proteins were 
selected.  The recombinant proteins corresponding to identified proteins were 
synthesized with Gateway entry clones using an in vitro wheat germ cell-free 
protein synthesis system (15).  The recombinant proteins were solubilized in 
lysis buffer (62.5 mM Tris-HCl (pH 6.8), 2% SDS, 10% glycerol, 5% 
2-mercaptoethanol, 0.001% BPB, and 1 M phenylmethylsulfonyl fluoride) and 
spotted onto PVDF membranes using a micro-dot-blot array (Kakengeneqs Co., 
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Ltd., Chiba, Japan).  After blocking with Tris-buffered saline with 2% Tween20 
for 60 min at R/T, the membranes were reacted with a 400-times dilution of each 
serum from patients with BC or healthy controls with 0.05% casein/TBST for 15 h 
at 4°C.  The membranes were washed 3 times with TBST for 5 min each at R/T 
and reacted with 1,000-times diluted HRP-conjugated rabbit anti-human IgG 
(DAKO) with 0.05% casein/TBST for 30 min at R/T.  After a further 3 washings 
with TBST for 5 min each, signals were developed using Immobilon Western 
Chemiluminescent HRP Substrate (Millipore Corp.).  The signal intensities were 
analyzed using DotBlotChip System software (version 4.0; Dynacom Co., Ltd., 
Chiba, Japan).  Each normalized signal was represented by the positive intensity 
minus the background intensity around the spot.  
 
2-7. Statistical analysis  
Significant differences between clinical characteristics and serum IgG levels of 
AAbs were tested using the Mann-Whitney U-test.  The area under the curve 
(AUC) and best cut-off point were calculated employing receiver-operating 
characteristic curve (ROC) analysis.  Cumulative survival rates of patients were 
determined using the Kaplan-Meier method, and the significance of survival 
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differences between high and low serum IgG levels of AAbs was tested using the 
log-rank test.  Multivariate analysis was performed by employing the Cox 
proportional hazards regression model.   A P -value of < 0.05 was used to 
determine the level of significance.   All statistical analysis were performed 
using StatFlex software version 6.0 (Artech Co., Ltd., Osaka, Japan). 
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3. Results 
3-1. 2-DE immunoblot analysis  
The proteins extracted from culture supernatants of four BC cell lines were 
separated by 2-DE and transferred onto the PVDF membranes, and reacted with 
mixed sera of four patients each with high- or low-grade BCs.  As the results, we 
detected a total of 138 immunoreactive spots, of which 25 and 32 were detected 
only in patients with high- or low-grade BCs, respectively.  A total of 81 were 
detected in both groups (Fig. 1D). 
 
3-2. Identification of proteins recognized by autoantibodies 
The protein spots that matched immunoreactive spots on the membrane were 
excised from CBB-stained 2-DE gel (Fig. 1B, C) and underwent in-gel digestion 
and MALDI-TOF/TOF MS analysis.  As the results, in 133 of the 138 (96%) 
immunoreactive spots, 61 proteins were identified.  In 24 of 25 (96%) 
immunoreactive spots, 17 proteins were detected, and in 29 of 32 (90%) 
immunoreactive spots, 21 proteins were detected, in sera from high- or low-grade 
BC patients, respectively.  Of these, 14 proteins were classified as “secreted 
protein” according to the Gene Ontology database (http://www.geneontology.org/) 
- 14 - 
 
(Table 2).  
 
3-3. Dot-blot analysis of autoantibodies against identified proteins 
We synthesized 13 recombinant proteins using a wheat germ cell-free system 
except for a collagen alpha-1(VI) chain which we failed to synthesize (Table 2).  
Serum IgG levels of each AAb in 95 BC patients and 35 normal controls were 
investigated by dot-blot analysis with recombinant proteins.  In the results of 
univariate analysis, the mean value (±SD) of serum IgG levels of anti-calreticulin 
and matrix metalloproteinase-2 (MMP2) AAbs were 14.0 ± 4.4 and 47.1 ± 9.7 in 
BC patients, and 9.9 ± 2.0 and 34.6 ± 5.1 in normal controls, respectively.  All 
serum IgG levels of anti- calreticulin and MMP2 AAbs were significantly higher in 
BC patients than in normal controls (P < 0.01, Fig. 2A, B).  In addition, the mean 
value (±SD) of serum IgG levels of anti- calreticulin and MMP2 AAbs were 13.5 ± 
3.1 and 40.4 ± 9.8 in the patients with low-grade BC, and 14.0 ± 4.6 and 66.3 ± 9.0 
in those with high-grade BC, respectively.  The serum IgG level of anti-MMP2 
AAb was significantly higher in patients with high-grade than in low-grade BC (P 
< 0.01, Fig. 2D), but not for anti- calreticulin AAb (Fig. 2C).  No significant 
difference in serum IgG levels of other AAbs between BC patients and normal 
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controls was detected (data not shown). 
 
3-4. Validation of anti-calreticulin and -MMP2 autoantibodies between BC 
patients and normal controls 
Based on ROC analysis of anti- calreticulin AAb, an optimal cut-off value of 
10.6 was applied, and the diagnostic sensitivity and specificity for BC patients 
were 64.0 and 60.0%, respectively.  The AUC for anti- calreticulin AAb in BC 
patients compared to normal controls was 0.65 (95% confidence interval: 1.23 - 
5.89, Fig. 3A).  Regarding anti-MMP2 AAb, an optimal cut-off value of 34.6 was 
applied, and the diagnostic sensitivity and specificity for BC patients were 60.0 
and 62.0%, respectively.  The AUC for anti-MMP2 AAb in BC patients compared 
to normal controls was 0.59 (95% confidence interval: 0.73 - 3.45, Fig. 3B). 
 
3-5. Association of serum IgG levels of anti-calreticulin and MMP2 autoantibodies 
with clinical outcomes 
To estimate whether serum IgG levels of anti- calreticulin and MMP2 AAbs 
were of independent predictive value for recurrence-free survival or cancer 
specific-survival of BC patients, uni- and multivariate analyses were performed.  
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At a median follow-up of 62.3 months (range: 2 to 166.4), Kaplan-Meier projection 
indicated that there were no significant correlation between the serum IgG level 
of anti- calreticulin AAb and recurrence-free or cancer-specific survival (Fig. 3C).  
However, the serum IgG level of anti-MMP2 AAb was significantly correlated 
with cancer-specific survival (P<0.05; Fig. 3D).  In addition, multivariate 
analysis with Cox proportional hazards regression analysis revealed that the 
serum IgG level of anti-MMP2 AAb and pathological stage were significantly 
correlated with cancer-specific survival (P <0.05 each, Table 3).  These findings 
suggest that an increased serum IgG level of anti-MMP2 AAb is an independent 
predictor of poorer survival in BC patients.  
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4. Discussion 
Secreted proteins reflect various states of cells in real time and under specific 
conditions, participate in various physiological processes, and play crucial roles in 
pathological processes.  Thus, it has been suggested that the analysis of 
tumor-secreted proteins is a promising method to identify diagnostic biomarkers 
in cancer (6, 33, 40, 48).  Actually, several studies have revealed that secreted 
proteins, which could be biomarker candidates, are present in the conditioned 
media of several tumor cells (25, 27, 47). 
AAbs against tumor-associated antigens have been identified in sera from 
patients with colon, breast, lung, ovary, and bladder cancers (4, 7, 16, 36, 50).  
Thus, the application of the humoral immune response for the detection of cancer 
biomarkers has a great potential and has been suggested as ideal screening for 
cancer diagnosis and their prognostic value (17, 24).  Furthermore, the immune 
system is especially well adapted for the early detection of cancer, because AAbs 
can be detected before the appearance of other biomarkers or phenotypic 
alternations in an early stage of tumorigenesis (19). 
Therefore, we performed 2-DE/immunoblot analysis to identify secreted 
antigenic proteins that are recognized by AAbs in the sera of BC patients.  In this 
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study, we picked up 57 immunoreactive spots that specifically differentiate the 
histological grade of BC.  Furthermore, we confirmed the usefulness of identified 
AAbs as sero-diagnostic and/or -prognostic biomarkers for BC by dot-blot analysis.  
In the results, serum IgG levels of anti-calreticulin or MMP2 AAbs, which were 
identified in sera from patients with high-grade BC, were significantly higher in 
sera of BC patients than in normal controls.  In addition, the serum IgG level of 
anti-MMP2 AAb was significantly correlated with the histological grade of the 
tumor and cancer-specific survival.  
Calreticulin is diversely distributed in the cytoplasm, nucleus, plasma 
membrane, and extracellular spaces of cells.  Because of these different 
localizations, it has been implicated in many cellular functions, including 
Ca2+storage and signaling, lectin-like chaperoning, the regulation of gene 
expression, cell adhesion, migration, cellular proliferation, and autoimmunity (8, 
26, 31).  It has been reported that the overexpression of calreticulin was detected 
in tumor tissues and their sera of hepatocellular, colon, and lung cancers (18, 45, 
49), and associated with the migration and proliferation of tumor cells and a 
poorer prognosis in esophageal, gastric, and breast cancer patients (2, 5, 9).  
Interestingly, it has been suggested that there is a significant correlation between 
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calreticulin expression and the aggressiveness of BC.  The BC cells with 
calreticulin knockdown showed the suppression of proliferation, migration, and 
attachment, in contrast to the overexpression of calreticulin which enhanced cell 
migration and attachment (28).  In BC tissues, calreticulin expression was 
predominant in the cytoplasm of BC cells, and its expression was higher in BC 
cells than in normal urothelial cells (21).  Furthermore, higher levels of 
calreticulin were found in urine samples of patients with BC, but not in urological 
patients without BC, and urinary calreticulin has been proposed as a biomarker of 
BC (20).  Although it was reported that the detection sensitivity of serum 
calreticulin in BC patients was 73.0% (21), this is slightly higher than that in our 
present anti-calreticulin AAb study.  However, Heo et al. reported that serum 
tumor-associated AAbs can be detected in the early stage of BC before serum 
tumor-associated antigens are detectable (19).  Although calreticulin 
overexpression in tumor cells is well known, the mechanism of this increase have 
not been well defined.  Previous studies reported an elevated serum IgG level of 
anti-calreticulin AAb in patients from hepatocellular carcinoma, gallbladder 
adenocarcinoma, pancreatic adenocarcinoma, and breast cancer when compared 
to healthy controls (10, 34).  These data are concordant with our present results, 
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suggesting that humoral immunity against calreticulin may be associated with 
the overexpression of calreticulin. 
Matrix metalloproteinases play important roles in various tumorigenic 
processes, such as extracellular matrix remodeling, angiogenesis, apoptosis, 
epithelial-to-mesenchymal transition, and cell proliferation.  MMP2 (gelatinase 
A, 72 kDa gelatinase) is one of the enzymes of the matrix metalloproteinase 
family, known to be essential for the degradation of type IV collagen in tumor 
tissues (41).  Elevation of MMP2 has been reported in cancer tissues or sera from 
patients with breast, lung, gastric, ovarian, and bladder cancers.  An association 
between the expression levels and clinicopathological factors was also described 
(12-14, 29, 37-39, 43).  In BC, it has been reported that the overexpression of 
MMP2 was detected in biological samples, including tissue, sera, and urine, and 
associated with clinicopathological factors and/or a poorer prognosis (13, 14, 43).  
In BC tissues, MMP2 expression was detected mostly in the cytoplasm of BC cells, 
and its overexpression may be an independent prognostic biomarker for BC 
progression (43).  A majority of biomarker studies including MMP2 in patients 
with BC have focused on urine (35).  No detailed study on the detection 
sensitivity of serum/plasma MMP2 levels in BC patients has been conducted.  
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The diagnostic sensitivity of our present study for serum anti-MMP2 AAb in BC 
patients was 60.0%, being higher than that for urinary MMP2 (51.0%).  
Therefore, we expect that MMP2 and its AAb in biological samples have the 
potential to be tumor markers for BC.  To our knowledge, this is the first report 
regarding the sero-diagnostic potential of AAbs to calreticulin and MMP2 in BC.  
Our results demonstrated that serum IgG levels of anti- calreticulin and MMP2 
AAbs may be serological biomarkers for BC and, in addition, anti-MMP2 AAbs 
were associated with the histological grade of the tumor and cancer-specific 
survival of BC patients. 
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5. Conclusion 
We identified several secreted proteins that were recognized by AAbs in the 
sera of BC patients by proteomic analysis.  We also revealed that serum IgG 
levels of anti- calreticulin and -MMP2 AAbs were significantly higher in BC 
patients than in normal controls.  In addition, a higher serum IgG level of 
anti-MMP2 AAb was associated with a high-grade tumor and poorer prognosis of 
BC patients.  These data suggest that serum anti- calreticulin and MMP2 AAbs 
may be candidate sero-diagnostic and/or -prognostic markers for BC patients. 
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9. Figures and Tables 
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Table 1. Clinicopathological characteristics of bladder cancer patients 
Characteristics 
Number of patients (n = 
95) (%) 
Gender 
Male 73 (77) 
  Female 22 (33) 
Age 
Range 29 - 88 
  Median 71   
Stage 
NMIBC 63 (66) 
  MIBC 32 (44) 
Histological grade 
High 71 (75) 
  Low 24 (25) 
Carcinoma in situ 
Negative 90 (95) 
  Positive 5 (5) 
Nodal status 
N0 82 (86) 
  N1, N2 13 (14) 
Lymphovascular 
invasion 
M0 90 (95) 
  M1, M2 5 (5) 
NMIBC: non-muscle-invasive bladder cancer, MIBC: muscle-invasive bladder 
cancer, High: bladder cancer with high grade, Low: bladder cancer with low grade. 
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Table 2. Identified antigenic proteins in sera from high- or low-grade BC patients 
Gene symbol Accession 
number 
Protein name Histological 
grade 
CALR P27797 Calreticulin High 
CTSD P07339 Cathepsin D High 
SERPINB5 P36952 Serpin B5 High 
MMP2 P08253 Matrix metalloproteinase-2 High 
CPA4 Q9UI42 Carboxypeptidase A4 High 
COL6A1 P12109 Collagen alpha-1(VI) chain High 
FBLN1 P23142 Fibulin-1 Low 
MP10 
P09238 
Matrix 
metalloproteinase-10 
Low 
SPARC P09486 SPARC Low 
MMP1 P03956 Matrix metalloproteinase-1 Low 
CTSZ Q9UBR2 Cathepsin Z Low 
SPON2 Q9BUD6 Spondin-2 Low 
CTSL1 P07711 Cathepsin L1 Low 
QSOX1 O00391 Sulfhydryl oxidase 1 Low 
High: specifically detected in sera from high-grade BC patients. 
Low: specifically detected in sera from low-grade BC patients. 
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Table 3. Multivariate Cox proportional hazards regression analyses for prediction 
of recurrence and survival of bladder cancer patients 
 Recurrence-free survival Cancer-specific survival 
 HR 95%CI P  HR 95%CI P  
Anti-MMP2 AAb 0.77 0.33 - 1.81 N.S. 2.62  1.04 - 6.58 0.04 
Gender 0.93 0.46 - 1.88 N.S. 1.41 0.66 - 3.02 N.S. 
Pathological stage 1.34 0.65 - 2.79 N.S. 3.25  1.23 - 8.58 0.02 
Histological grade 1.51 0.65 - 3.50 N.S. 0.83  0.31 - 2.20 N.S. 
Lymphovascular 
invasion 0.74 0.25 - 2.22 N.S. 0.40 0.12 - 1.37 N.S. 
Nodal status 1.01 0.22 - 4.55 N.S. 0.49 0.10 - 2.46 N.S. 
HR: hazard ratio, CI: confidence interval, N.S.: not significant. 
Multivariate Cox proportional hazards regression analysis was used to estimate 
HR, with the corresponding 95% CI. 
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Figure 1. Detection of autoantibodies by 2-DE immunoblot analysis in sera from 
BC patients. 
 
The proteins extracted from culture supernatants of the BC cell lines were 
separated by 2-DE and transferred to PVDF membranes.  The membranes were 
incubated with mixed sera from BC patients (A).  Protein patterns of 
CBB-stained 2-DE gel (B).  Merged image of immunoreactive spots on the 
membranes and CBB-stained 2-DE gel (C).  By comparing immunoreactive 
patterns, 25 and 32 spots were specifically detected in patients with high- and 
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D
25
Low grade
3281
High grade
- 38 - 
 
low-grade BC, respectively (D).  The protein spots that matched immunoreactive 
ones on the 2-DE gel were excised and identified by MALDI-TOF/TOF MS.   
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Figure 2. Dot-blot analysis of serum IgG levels of anti- calreticulin and MMP2 
AAbs. 
 
Serum IgG levels of anti-calreticulin and MMP2 AAbs in sera from BC patients 
and normal controls were detected by dot-blot analysis.  The normalized 
intensity was calculated with the Mann-Whitney U-test.  The serum IgG level of 
anti-calreticulin AAb was significantly higher in BC patients than in normal 
controls (A). No significant difference was detected between high- and low-grade 
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tumors (C).  The serum IgG level of anti-MMP2 AAb was significantly higher in 
BC patients than in normal controls (B) and significantly higher in high-grade 
than in low-grade BC patients (D).  N.S.: not significant 
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Figure 3. Receiver-operating characteristic curve (ROC) analysis for BC and the 
probability of cancer-specific survival according to serum IgG levels of 
anti-calreticulin and MMP2 AAbs. 
 
The corresponding areas under the curves (AUC) of serum IgG levels of 
anti-calreticulin (A) and anti-MMP2 (B) AAbs in BC patients compared to normal 
controls were 0.65 and 0.59, respectively.  Regarding cancer-specific survival in 
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BC patients, a significant correlation was recognized with the IgG level of 
anti-MMP2 AAb (D), but not with anti-calreticulin AAb (C).  N.S.: not significant 
